Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo

被引:212
作者
Li, M
Davey, GM
Sutherland, RM
Kurts, C
Lew, AM
Hirst, C
Carbone, FR [1 ]
Heath, WR
机构
[1] PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic 3050, Australia
[2] PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Transplantat & Autoimmun Div, Parkville, Vic 3050, Australia
[3] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia
[4] Monash Univ Sch Med, Dept Pathol & Immunol, Prahran, Vic, Australia
[5] Clin Rhein Westfal TH Aachen, Dept Nephrol & Immunol, Aachen, Germany
关键词
D O I
10.4049/jimmunol.166.10.6099
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To better understand the antigenic requirements for cross-presentation, we compared the in vivo efficiency of presentation of cell-associated vs soluble OVA with the OT-I (CD8) and OT-II (CD4) TCR transgenic lines. Cross-presentation of cell-associated OVA was very efficient, requiring as little as 21 ng of OVA to activate OT-II cells and 100-fold less to activate OT-I cells. In contrast, soluble OVA was presented inefficiently, requiring at least 10,000 ng OVA for activation of either T cell subset. Thus, cell-associated OVA was presented 500-fold more efficiently than soluble OVA to CD4 T cells and 50,000-fold more efficiently to CD8 T cells. These data, which represent the first quantitative in vivo analysis of cross-presentation, show that cell-associated OVA is very efficiently presented via the class 1 pathway.
引用
收藏
页码:6099 / 6103
页数:5
相关论文
共 25 条
[1]   CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells [J].
Adler, AJ ;
Marsh, DW ;
Yochum, GS ;
Guzzo, JL ;
Nigam, A ;
Nelson, WG ;
Pardoll, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (10) :1555-1564
[2]   Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[3]   Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes [J].
Albert, ML ;
Pearce, SFA ;
Francisco, LM ;
Sauter, B ;
Roy, P ;
Silverstein, RL ;
Bhardwaj, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) :1359-1368
[4]   Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements [J].
Barnden, MJ ;
Allison, J ;
Heath, WR ;
Carbone, FR .
IMMUNOLOGY AND CELL BIOLOGY, 1998, 76 (01) :34-40
[5]  
Bellone M, 1997, J IMMUNOL, V159, P5391
[6]   Induction of a CD8(+) cytotoxic T lymphocyte response by cross-priming requires cognate CD4(+) T cell help [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Miller, JFAP ;
Heath, WR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :65-70
[7]   DNA immunization: Induction of higher avidity antibody and effect of route on T cell cytotoxicity [J].
Boyle, JS ;
Silva, A ;
Brady, JL ;
Lew, AM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14626-14631
[8]   Cross-presentation: A general mechanism for CTL immunity and tolerance [J].
Carbone, FR ;
Kurts, C ;
Bennett, SRM ;
Miller, JFAP ;
Heath, WR .
IMMUNOLOGY TODAY, 1998, 19 (08) :368-373
[9]   CLASS-I-RESTRICTED PROCESSING AND PRESENTATION OF EXOGENOUS CELL-ASSOCIATED ANTIGEN INVIVO [J].
CARBONE, FR ;
BEVAN, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (02) :377-387
[10]   CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo [J].
den Haan, JMM ;
Lehar, SM ;
Bevan, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (12) :1685-1695